A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate orEnzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) PreviouslyTreated With Next-generation Hormonal Agent (NHA) and Taxane

Project: Research project

Project Details

Description

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane
StatusActive
Effective start/end date12/27/23 → 12/31/33

Funding

  • MERCK

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint